Screening methods for targets for cancer therapy
US-2018156800-A1 · Jun 7, 2018 · US
Compositions for identification of membrane targets for enhancement of T cell activity against cancer
US12297428B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12297428-B2 |
| Application number | US-201917264691-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 31, 2019 |
| Priority date | Aug 1, 2018 |
| Publication date | May 13, 2025 |
| Grant date | May 13, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. An adeno-associated virus (AAV) vector comprising the nucleic acid sequence set forth in SEQ ID NO: 69,821.
Assignees
Inventors
Classifications
Epidermal growth factor receptors [EGFR] · CPC title
Cancer antigens · CPC title
Chimeric antigen receptors [CAR] · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
characterized by the route of administration · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12297428B2 cover?
- The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.
- Who is the assignee on this patent?
- Univ Yale
- What technology area does this patent fall under?
- Primary CPC classification C12N15/111. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).